1Harries AD,Nyangulu DS,Hargreaves NJ,et al.Preventing antiretroviral anarchy in Africa[J].Lancet,2001,358:410-414.
2Fischl M,Castro J,Monroig,et al.Impact of DOT on long-term outcomes in HIV clinical trials.8th Conference on Retroviruses and Opportunistic Infections[C].Chicago,IL,February 4-8,2001.
3Mitty JA,Stone VE,Sands M,et al.Directly observed therapy for the treatment of people with human immunodeficiency virus infection:a work in progress[J].Clin Infect Dis,2002,35:984-990.
4Farmer P,Leandre F,Mukherjee JS,et al.Community-based approaches to HIV treatment in resource-poor settings[J].The Lancet,2001,358:404-409.
5Deeks SG,Wrin T,Liegler T,et al.Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.N Engl J Med,2001,344:472-480.
6Stenzel MS,McKenzie M,Adelson-Mitty J,et al.Modified directly observed therapy (MDOT) to enhance adherence to highly activeantiretroviral therapy (HAART):12 month follow-up[C].Program and abstracts of the Ⅷ International AIDS Conference; July 9-14,2000; Durban,South Africa.Abstract ThPeB4992.
7Bangsberg DR,Porco TC,Kagay C,et al.Modeling the impact of modified directly observed antiretroviral yherapy on HIV suppression and resistance,disease progression,and death[J].Clinical Infectious Diseases,2004,38,414.
8Bangsberg DR,Hecht FM,Clague H,et al.Provider assessment of adherence to HIV antiretroviral therapy[J].J Acquir Immune Defic Syndr,2001,26:435-442.
9Bangsberg DR,Mundy LM,Tulsky JP.Expanding directly observed therapy:tuberculosis to human immunodeficiency virus[J].Am J Med,2001,110:664-666.
10Babudieri S,Aceti A,D'Offizi GP,et al.Directly observed therapy to treat HIV infection in prisoners.JAMA,July 12,2000,284(2):179-180.
3Simoni J,Frick P, Pantalone D,et al.Antiretroviral Adherence Inter- ventions: A Review of Current Literature and Ongoing Studies[J]. Trop HIV Med,2003,11 (6): 185-198.
